P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy
Abstract
:1. Introduction
2. Results
2.1. P2X7 Targeting by A438079 Improves Functional, Biochemical and Morphological Parameters in Sgca Mice
2.2. A438079 Reduces Muscular Fibrosis and Inflammation in Sgca Mice
2.3. A438079 Reduces Innate Inflammatory Cells and Increases T Regulatory Lymphocytes in Limb Muscles of Sgca Mice
3. Discussion
4. Materials and Methods
4.1. In Vivo Experiments
4.2. Four-Limb Hanging Test
4.3. Histological Studies, Imaging and Analysis
4.4. Immunofluorescence
4.5. Flow Cytometry
4.6. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alonso-Pérez, J.; González-Quereda, L.; Bello, L.; Guglieri, M.; Straub, V.; Gallano, P.; Semplicini, C.; Pegoraro, E.; Zangaro, V.; Nascimento, A.; et al. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain A J. Neurol. 2020, 143, 2696–2708. [Google Scholar] [CrossRef] [PubMed]
- Vainzof, M.; Souza, L.S.; Gurgel-Giannetti, J.; Zatz, M. Sarcoglycanopathies: An update. Neuromuscul. Disord. 2021, 31, 1021–1027. [Google Scholar] [CrossRef] [PubMed]
- Sandona, D.; Betto, R. Sarcoglycanopathies: Molecular pathogenesis and therapeutic prospects. Expert Rev. Mol. Med. 2009, 11, e28. [Google Scholar] [CrossRef]
- Petrof, B.J.; Shrager, J.B.; Stedman, H.H.; Kelly, A.M.; Sweeney, H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 1993, 90, 3710–3714. [Google Scholar] [CrossRef] [Green Version]
- Tidball, J.G.; Welc, S.S.; Wehling-Henricks, M. Immunobiology of Inherited Muscular Dystrophies. Compr. Physiol. 2018, 8, 1313–1356. [Google Scholar]
- Kirschner, J.; Lochmüller, H. Sarcoglycanopathies. Handb. Clin. Neurol. 2011, 101, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Mercuri, E.; Bönnemann, C.G.; Muntoni, F. Muscular dystrophies. Lancet 2019, 394, 2025–2038. [Google Scholar] [CrossRef]
- Fanin, M.; Angelini, C. Regeneration in sarcoglycanopathies: Expression studies of sarcoglycans and other muscle proteins. J. Neurol. Sci. 1999, 165, 170–177. [Google Scholar] [CrossRef]
- Rosenberg, A.S.; Puig, M.; Nagaraju, K.; Hoffman, E.P.; Villalta, S.A.; Rao, V.A.; Wakefield, L.M.; Woodcock, J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci. Transl. Med. 2015, 7, 299rv294. [Google Scholar] [CrossRef] [Green Version]
- Panicucci, C.; Baratto, S.; Raffaghello, L.; Tonin, P.; D’Amico, A.; Tasca, G.; Traverso, M.; Fiorillo, C.; Minetti, C.; Previtali, S.C.; et al. Muscle inflammatory pattern in alpha- and gamma-sarcoglycanopathies. Clin. Neuropathol. 2021, 40, 310–318. [Google Scholar] [CrossRef]
- Betto, R.; Senter, L.; Ceoldo, S.; Tarricone, E.; Biral, D.; Salviati, G. Ecto-ATPase activity of alpha-sarcoglycan (adhalin). J. Biol. Chem. 1999, 274, 7907–7912. [Google Scholar] [CrossRef] [Green Version]
- Sandona, D.; Gastaldello, S.; Martinello, T.; Betto, R. Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan. Biochem. J. 2004, 381, 105–112. [Google Scholar] [CrossRef]
- Di Virgilio, F.; Adinolfi, E. Extracellular purines, purinergic receptors and tumor growth. Oncogene 2017, 36, 293–303. [Google Scholar] [CrossRef]
- Di Virgilio, F.; Sarti, A.C.; Grassi, F. Modulation of innate and adaptive immunity by P2X ion channels. Curr. Opin. Immunol. 2018, 52, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Munoz-Planillo, R.; Kuffa, P.; Martinez-Colon, G.; Smith, B.L.; Rajendiran, T.M.; Nunez, G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38, 1142–1153. [Google Scholar] [CrossRef] [Green Version]
- MacKenzie, A.; Wilson, H.L.; Kiss-Toth, E.; Dower, S.K.; North, R.A.; Surprenant, A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001, 15, 825–835. [Google Scholar] [CrossRef]
- Karmakar, M.; Katsnelson, M.A.; Dubyak, G.R.; Pearlman, E. Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP. Nat. Commun. 2016, 7, 10555. [Google Scholar] [CrossRef] [Green Version]
- Gazzerro, E.; Baldassari, S.; Assereto, S.; Fruscione, F.; Pistorio, A.; Panicucci, C.; Volpi, S.; Perruzza, L.; Fiorillo, C.; Minetti, C.; et al. Enhancement of Muscle T Regulatory Cells and Improvement of Muscular Dystrophic Process in mdx Mice by Blockade of Extracellular ATP/P2X Axis. Am. J. Pathol. 2015, 185, 3349–3360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeung, D.; Zablocki, K.; Lien, C.F.; Jiang, T.; Arkle, S.; Brutkowski, W.; Brown, J.; Lochmuller, H.; Simon, J.; Barnard, E.A.; et al. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. FASEB J. 2006, 20, 610–620. [Google Scholar] [CrossRef]
- Rawat, R.; Cohen, T.V.; Ampong, B.; Francia, D.; Henriques-Pons, A.; Hoffman, E.P.; Nagaraju, K. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am. J. Pathol. 2010, 176, 2891–2900. [Google Scholar] [CrossRef]
- Young, C.N.; Brutkowski, W.; Lien, C.F.; Arkle, S.; Lochmuller, H.; Zablocki, K.; Gorecki, D.C. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: Relationship to pathology and potential target for treatment. J. Cell. Mol. Med. 2012, 16, 1026–1037. [Google Scholar] [CrossRef]
- Cea, L.A.; Puebla, C.; Cisterna, B.A.; Escamilla, R.; Vargas, A.A.; Frank, M.; Martinez-Montero, P.; Prior, C.; Molano, J.; Esteban-Rodriguez, I.; et al. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis. Cell. Mol. Life Sci. 2016, 73, 2583–2599. [Google Scholar] [CrossRef] [PubMed]
- Gorecki, D.C. P2X7 purinoceptor as a therapeutic target in muscular dystrophies. Curr. Opin. Pharmacol. 2019, 47, 40–45. [Google Scholar] [CrossRef] [Green Version]
- Sinadinos, A.; Young, C.N.; Al-Khalidi, R.; Teti, A.; Kalinski, P.; Mohamad, S.; Floriot, L.; Henry, T.; Tozzi, G.; Jiang, T.; et al. P2RX7 purinoceptor: A therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. PLoS Med. 2015, 12, e1001888. [Google Scholar] [CrossRef] [PubMed]
- Gazzerro, E.; Baratto, S.; Assereto, S.; Baldassari, S.; Panicucci, C.; Raffaghello, L.; Scudieri, P.; De Battista, D.; Fiorillo, C.; Volpi, S.; et al. The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of alpha-Sarcoglycan–Deficient Muscular Dystrophy. Am. J. Pathol. 2019, 189, 354–369. [Google Scholar] [CrossRef] [PubMed]
- Nelson, D.W.; Gregg, R.J.; Kort, M.E.; Perez-Medrano, A.; Voight, E.A.; Wang, Y.; Grayson, G.; Namovic, M.T.; Donnelly-Roberts, D.L.; Niforatos, W.; et al. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 2006, 49, 3659–3666. [Google Scholar] [CrossRef]
- Pozsgai, E.R.; Griffin, D.A.; Heller, K.N.; Mendell, J.R.; Rodino-Klapac, L.R. β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice. Gene Ther. 2016, 23, 57–66. [Google Scholar] [CrossRef]
- Di Virgilio, F.; Dal Ben, D.; Sarti, A.C.; Giuliani, A.L.; Falzoni, S. The P2X7 Receptor in Infection and Inflammation. Immunity 2017, 47, 15–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Young, C.N.; Sinadinos, A.; Lefebvre, A.; Chan, P.; Arkle, S.; Vaudry, D.; Gorecki, D.C. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Autophagy 2015, 11, 113–130. [Google Scholar] [CrossRef]
- Young, C.N.J.; Chira, N.; Rog, J.; Al-Khalidi, R.; Benard, M.; Galas, L.; Chan, P.; Vaudry, D.; Zablocki, K.; Gorecki, D.C. Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition. J. Mol. Cell. Biol. 2017, 10, 229–242. [Google Scholar] [CrossRef] [Green Version]
- Panicucci, C.; Raffaghello, L.; Bruzzone, S.; Baratto, S.; Principi, E.; Minetti, C.; Gazzerro, E.; Bruno, C. eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases. Int. J. Mol. Sci. 2020, 21, 5963. [Google Scholar] [CrossRef]
- Savio, L.E.B.; de Andrade Mello, P.; da Silva, C.G.; Coutinho-Silva, R. The P2X7 Receptor in Inflammatory Diseases: Angel or Demon? Front. Pharmacol. 2016, 9, 52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Virgilio, F. Novel data point to a broader mechanism of action of oxidized ATP: The P2X7 receptor is not the only target. Br. J. Pharmacol. 2003, 140, 441–443. [Google Scholar] [CrossRef] [Green Version]
- De Marchi, E.; Orioli, E.; Dal Ben, D.; Adinolfi, E. P2X7 Receptor as a Therapeutic Target. Adv. Protein Chem. Struct. Biol. 2016, 104, 39–79. [Google Scholar]
- Beigi, R.D.; Kertesy, S.B.; Aquilina, G.; Dubyak, G.R. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br. J. Pharmacol. 2003, 140, 507–519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Figliuolo, V.R.; Chaves, S.P.; Santoro, G.F.; Coutinho, C.M.; Meyer-Fernandes, J.R.; Rossi-Bergmann, B.; Coutinho-Silva, R. Periodate-oxidized ATP modulates macrophage functions during infection with Leishmania amazonensis. Cytom. A 2014, 85, 588–600. [Google Scholar] [CrossRef]
- Craighead, M.W.; Middlehurst, K.M.; LeFeuvre, R.; Kimber, I.; Rothwell, N.J. Oxidised adenosine 5′-triphosphate, a P2X(7) antagonist, is toxic to rat cerebellar granule neurones in vitro. Neurosci. Lett. 2001, 311, 77–80. [Google Scholar] [CrossRef]
- Donnelly-Roberts, D.L.; Namovic, M.T.; Han, P.; Jarvis, M.F. Mammalian P2X7 receptor pharmacology: Comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. Pharmacol. 2009, 157, 1203–1214. [Google Scholar] [CrossRef] [Green Version]
- Honore, P.; Donnelly-Roberts, D.; Namovic, M.T.; Hsieh, G.; Zhu, C.Z.; Mikusa, J.P.; Hernandez, G.; Zhong, C.; Gauvin, D.M.; Chandran, P.; et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 2006, 319, 1376–1385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGaraughty, S.; Chu, K.L.; Namovic, M.T.; Donnelly-Roberts, D.L.; Harris, R.R.; Zhang, X.F.; Shieh, C.C.; Wismer, C.T.; Zhu, C.Z.; Gauvin, D.M.; et al. P2X7-related modulation of pathological nociception in rats. Neuroscience 2007, 146, 1817–1828. [Google Scholar] [CrossRef]
- Teixeira, J.M.; Oliveira, M.C.; Parada, C.A.; Tambeli, C.H. Peripheral mechanisms underlying the essential role of P2X7 receptors in the development of inflammatory hyperalgesia. Eur. J. Pharmacol. 2010, 644, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Jimenez-Pacheco, A.; Mesuret, G.; Sanz-Rodriguez, A.; Tanaka, K.; Mooney, C.; Conroy, R.; Miras-Portugal, M.T.; Diaz-Hernandez, M.; Henshall, D.C.; Engel, T. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 2013, 54, 1551–1561. [Google Scholar] [CrossRef]
- Mesuret, G.; Engel, T.; Hessel, E.V.; Sanz-Rodriguez, A.; Jimenez-Pacheco, A.; Miras-Portugal, M.T.; Diaz-Hernandez, M.; Henshall, D.C. P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci. Ther. 2014, 20, 556–564. [Google Scholar] [CrossRef]
- Marcellino, D.; Suárez-Boomgaard, D.; Sánchez-Reina, M.D.; Aguirre, J.A.; Yoshitake, T.; Yoshitake, S.; Hagman, B.; Kehr, J.; Agnati, L.F.; Fuxe, K.; et al. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: Studies with the P2X(7) receptor antagonist A-438079. J. Neural Transm. 2010, 117, 681–687. [Google Scholar] [CrossRef] [PubMed]
- Khalafalla, M.G.; Woods, L.T.; Camden, J.M.; Khan, A.A.; Limesand, K.H.; Petris, M.J.; Erb, L.; Weisman, G.A. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy. J. Biol. Chem. 2017, 292, 16626–16637. [Google Scholar] [CrossRef] [Green Version]
- Sociali, G.; Visigalli, D.; Prukop, T.; Cervellini, I.; Mannino, E.; Venturi, C.; Bruzzone, S.; Sereda, M.W.; Schenone, A. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiol. Dis. 2016, 95, 145–157. [Google Scholar] [CrossRef] [PubMed]
- Folker, E.S.; Baylies, M.K. Nuclear positioning in muscle development and disease. Front. Physiol. 2013, 4, 363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gentile, D.; Natale, M.; Lazzerini, P.E.; Capecchi, P.L.; Laghi-Pasini, F. The role of P2X7 receptors in tissue fibrosis: A brief review. Purinergic Signal. 2015, 11, 435–440. [Google Scholar] [CrossRef] [Green Version]
- Villalta, S.A.; Rosenberg, A.S.; Bluestone, J.A. The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis. 2015, 3, e1010966. [Google Scholar] [CrossRef] [Green Version]
- Ingersoll, M.A.; Platt, A.M.; Potteaux, S.; Randolph, G.J. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 2011, 32, 470–477. [Google Scholar] [CrossRef] [Green Version]
- Mojumdar, K.; Liang, F.; Giordano, C.; Lemaire, C.; Danialou, G.; Okazaki, T.; Bourdon, J.; Rafei, M.; Galipeau, J.; Divangahi, M.; et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. EMBO Mol. Med. 2014, 6, 1476–1492. [Google Scholar] [CrossRef]
- Villalta, S.A.; Nguyen, H.X.; Deng, B.; Gotoh, T.; Tidball, J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 2009, 18, 482–496. [Google Scholar] [CrossRef] [Green Version]
- Kranig, S.A.; Tschada, R.; Braun, M.; Patry, C.; Poschl, J.; Frommhold, D.; Hudalla, H. Dystrophin deficiency promotes leukocyte recruitment in mdx mice. Pediatr. Res. 2019, 86, 188–194. [Google Scholar] [CrossRef]
- Hodgetts, S.; Radley, H.; Davies, M.; Grounds, M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul. Disord. 2006, 16, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Tulangekar, A.; Sztal, T.E. Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration. Biomedicines 2021, 9, 1366. [Google Scholar] [CrossRef]
- Arecco, N.; Clarke, C.J.; Jones, F.K.; Simpson, D.M.; Mason, D.; Beynon, R.J.; Pisconti, A. Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation. Sci. Rep. 2016, 6, 24708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al-Khalidi, R.; Panicucci, C.; Cox, P.; Chira, N.; Róg, J.; Young, C.N.J.; McGeehan, R.E.; Ambati, K.; Ambati, J.; Zabłocki, K.; et al. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism. Acta Neuropathol. Commun. 2018, 6, 27. [Google Scholar] [CrossRef]
- Pelegrin, P. Targeting interleukin-1 signaling in chronic inflammation: Focus on P2X(7) receptor and Pannexin-1. Drug News Perspect. 2008, 21, 424–433. [Google Scholar] [CrossRef] [PubMed]
- Pelegrin, P.; Barroso-Gutierrez, C.; Surprenant, A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 2008, 180, 7147–7157. [Google Scholar] [CrossRef] [Green Version]
- Pizzirani, C.; Ferrari, D.; Chiozzi, P.; Adinolfi, E.; Sandonà, D.; Savaglio, E.; Di Virgilio, F. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 2007, 109, 3856–3864. [Google Scholar] [CrossRef] [Green Version]
- Kawamura, H.; Kawamura, T.; Kanda, Y.; Kobayashi, T.; Abo, T. Extracellular ATP-stimulated macrophages produce macrophage inflammatory protein-2 which is important for neutrophil migration. Immunology 2012, 136, 448–458. [Google Scholar] [CrossRef]
- Villalta, S.A.; Rosenthal, W.; Martinez, L.; Kaur, A.; Sparwasser, T.; Tidball, J.G.; Margeta, M.; Spencer, M.J.; Bluestone, J.A. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 2014, 6, 258ra142. [Google Scholar] [CrossRef] [PubMed]
- Burzyn, D.; Kuswanto, W.; Kolodin, D.; Shadrach, J.L.; Cerletti, M.; Jang, Y.; Sefik, E.; Tan, T.G.; Wagers, A.J.; Benoist, C.; et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013, 155, 1282–1295. [Google Scholar] [CrossRef] [Green Version]
- Quattrocelli, M.; Zelikovich, A.S.; Salamone, I.M.; Fischer, J.A.; McNally, E.M. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. J. Neuromuscul. Dis. 2021, 8, 39–52. [Google Scholar] [CrossRef] [PubMed]
- Connolly, A.M.; Pestronk, A.; Mehta, S.; Al-Lozi, M. Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve 1998, 21, 1549–1553. [Google Scholar] [CrossRef]
- Angelini, C.; Fanin, M.; Menegazzo, E.; Freda, M.P.; Duggan, D.J.; Hoffman, E.P. Homozygous alpha-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve 1998, 21, 769–775. [Google Scholar] [CrossRef]
- Griffin, D.A.; Pozsgai, E.R.; Heller, K.N.; Potter, R.A.; Peterson, E.L.; Rodino-Klapac, L.R. Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy. Hum. Gene Ther. 2021, 32, 390–404. [Google Scholar] [CrossRef] [PubMed]
- Turan, S.; Farruggio, A.P.; Srifa, W.; Day, J.W.; Calos, M.P. Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy. Mol. Ther. J. Am. Soc. Gene Ther. 2016, 24, 685–696. [Google Scholar] [CrossRef] [Green Version]
- Pozsgai, E.; Griffin, D.; Potter, R.; Sahenk, Z.; Lehman, K.; Rodino-Klapac, L.R.; Mendell, J.R. Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegener. Dis. Manag. 2021, 11, 411–429. [Google Scholar] [CrossRef] [PubMed]
- Chu, M.L.; Moran, E. The Limb-Girdle Muscular Dystrophies: Is Treatment on the Horizon? Neurotherapeutics 2018, 15, 849–862. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Escobar, H.; Krause, A.; Keiper, S.; Kieshauer, J.; Müthel, S.; de Paredes, M.G.; Metzler, E.; Kühn, R.; Heyd, F.; Spuler, S. Base editing repairs an SGCA mutation in human primary muscle stem cells. JCI Insight 2021, 6, e145994. [Google Scholar] [CrossRef] [PubMed]
- Shokoples, B.G.; Paradis, P.; Schiffrin, E.L. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 186–199. [Google Scholar] [CrossRef] [PubMed]
- Recourt, K.; van der Aart, J.; Jacobs, G.; de Kam, M.; Drevets, W.; van Nueten, L.; Kanhai, K.; Siebenga, P.; Zuiker, R.; Ravenstijn, P.; et al. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. J. Psychopharmacol. 2020, 34, 1030–1042. [Google Scholar] [CrossRef]
- Duclos, F.; Straub, V.; Moore, S.A.; Venzke, D.P.; Hrstka, R.F.; Crosbie, R.H.; Durbeej, M.; Lebakken, C.S.; Ettinger, A.J.; van der Meulen, J.; et al. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J. Cell. Biol. 1998, 142, 1461–1471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Raffaghello, L.; Principi, E.; Baratto, S.; Panicucci, C.; Pintus, S.; Antonini, F.; Del Zotto, G.; Benzi, A.; Bruzzone, S.; Scudieri, P.; et al. P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy. Pharmaceuticals 2022, 15, 89. https://doi.org/10.3390/ph15010089
Raffaghello L, Principi E, Baratto S, Panicucci C, Pintus S, Antonini F, Del Zotto G, Benzi A, Bruzzone S, Scudieri P, et al. P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy. Pharmaceuticals. 2022; 15(1):89. https://doi.org/10.3390/ph15010089
Chicago/Turabian StyleRaffaghello, Lizzia, Elisa Principi, Serena Baratto, Chiara Panicucci, Sara Pintus, Francesca Antonini, Genny Del Zotto, Andrea Benzi, Santina Bruzzone, Paolo Scudieri, and et al. 2022. "P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy" Pharmaceuticals 15, no. 1: 89. https://doi.org/10.3390/ph15010089